Survodutide

Survodutide (BI 456906) Research Peptide – Dual GLP-1/Glucagon Receptor Agonist, Metabolic & Liver Research

Investigational Dual-Receptor Peptide for GLP-1R/GCGR Signaling, Body Weight Regulation, Energy Metabolism, MASLD, MASH & Cardiometabolic Research

Survodutide, also known as BI 456906, is an investigational peptide developed to activate two metabolically important receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

This dual-receptor pharmacology distinguishes Survodutide from selective GLP-1 receptor agonists such as semaglutide and from dual GIP/GLP-1 receptor agonists such as tirzepatide.

Survodutide has attracted considerable scientific interest because it combines GLP-1-associated effects on appetite regulation and glucose-dependent insulin secretion with glucagon receptor-associated effects on hepatic metabolism and energy regulation.

Clinical development has focused on obesity, overweight, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH).

By October 2026, multiple phase 3 studies had reported results involving body weight and liver-related endpoints.

However, Survodutide remains an investigational compound and is not an FDA-approved medicine.

The findings from pharmaceutical clinical trials do not establish the safety or suitability of research-grade Survodutide for human administration.

ICAME Pharmacy Survodutide is intended exclusively for legitimate laboratory research and development purposes.

FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.

What Is Survodutide?

Survodutide is a synthetic, chemically modified peptide designed to act as a dual agonist of GLP-1R and GCGR.

Its research development name is BI 456906.

The compound belongs to the broader field of incretin and glucagon-based peptide pharmacology.

Unlike natural glucagon or GLP-1, Survodutide incorporates structural modifications intended to produce a differentiated receptor-activation profile and prolonged pharmacological exposure.

Its molecular design includes a lipid-associated modification that contributes to its extended pharmacokinetic behavior.

Main Research Areas

• GLP-1 receptor signaling

• Glucagon receptor signaling

• Dual-receptor agonism

• Appetite and satiety regulation

• Body weight regulation

• Hepatic lipid metabolism

• Energy expenditure

• Glucose homeostasis

• Insulin and glucagon physiology

• Metabolic dysfunction-associated steatotic liver disease

• Metabolic dysfunction-associated steatohepatitis

• Liver fat accumulation

• Liver inflammation and fibrosis biomarkers

• Cardiometabolic risk factors

• Peptide pharmacokinetics

• Receptor selectivity and potency

• Metabolic peptide structure–activity relationships

The compound is particularly relevant to research examining how simultaneous GLP-1R and GCGR activation differs from selective incretin receptor activation.

Survodutide Molecular Structure and Chemical Properties

Survodutide is a modified peptide containing nonstandard structural elements and a lipid-linked side chain.

Its complete chemical identity cannot be adequately represented by a conventional one-letter amino acid sequence alone.

Molecular Characteristics

These molecular values refer to the defined Survodutide molecular entity.

Actual analytical measurements may depend on the specified chemical form, counterions, hydration and material composition.

Survodutide Amino Acid Sequence

The peptide backbone is described in technical references using the following abbreviated representation:

H–Ac4c–QGTFTSDYSKYLDERAAKDFI–X–WLESA–NH₂

In this notation:

Ac4c represents 1-aminocyclobutane-1-carboxylic acid, a nonstandard amino acid.

X represents a modified lysine residue bearing a glycine–serine-containing linker and a C18 diacid-associated lipid moiety.

The C-terminal end is amidated.

This notation is an abbreviated structural representation, not a standard unmodified protein sequence.

Why the Modified Structure Matters

Survodutide's structural features are relevant to:

Receptor recognition

Receptor activation

Proteolytic stability

Albumin-associated pharmacokinetics

Prolonged systemic exposure

Analytical identification

Peptide formulation research

The lipidated modification is an important distinction between Survodutide and naturally occurring GLP-1 or glucagon.

Understanding GLP-1 and Glucagon

Survodutide combines activity at two receptors involved in metabolic regulation.

Although GLP-1 and glucagon are related peptide hormones, their physiological roles are not identical.

What Is GLP-1?

Glucagon-like peptide-1 is an incretin hormone released primarily from intestinal enteroendocrine L cells following nutrient intake.

GLP-1 participates in regulation of glucose homeostasis, appetite and gastrointestinal physiology.

Its established effects include:

Glucose-dependent insulin secretion

Suppression of inappropriate glucagon secretion under certain conditions

Delayed gastric emptying

Central appetite-related signaling

Food intake regulation

These actions help explain why GLP-1 receptor agonists have become important in metabolic medicine.

What Is Glucagon?

Glucagon is a peptide hormone produced primarily by pancreatic alpha cells.

It acts on the glucagon receptor, particularly in the liver.

Glucagon contributes to regulation of hepatic glucose production and nutrient metabolism.

Its effects include:

Hepatic glycogenolysis

Gluconeogenesis

Hepatic substrate metabolism

Lipid-related metabolic signaling

Fasting-associated energy regulation

Glucagon receptor activation can increase hepatic glucose output.

This creates an important pharmacological challenge when developing dual GLP-1/glucagon receptor agonists.

How Does Survodutide Work?

Survodutide activates both GLP-1R and GCGR.

These receptors belong to the class B family of G protein-coupled receptors.

Both receptors are strongly associated with stimulatory G protein signaling and intracellular cyclic AMP production.

However, their downstream physiological effects differ across tissues.

Dual-Receptor Mechanism

Survodutide (BI 456906)

↓

GLP-1 Receptor Activation

• Glucose-dependent insulin secretion

• Appetite-related signaling

• Food intake regulation

• Gastric emptying effects

Glucagon Receptor Activation

• Hepatic metabolic signaling

• Glucose production pathways

• Lipid metabolism

• Potential energy expenditure effects

↓

Integrated Metabolic Response

↓

Changes in Body Weight, Glycemic Parameters and Liver-Related Endpoints

The resulting response depends on receptor potency, tissue distribution, physiological state and experimental conditions.

It is not scientifically accurate to assume that every observed metabolic effect can be attributed to a single receptor.

Survodutide and GLP-1 Receptor Research

The GLP-1 receptor is expressed in several tissues involved in metabolic regulation.

GLP-1R is a class B GPCR.

Its activation commonly involves the Gs–adenylyl cyclase–cAMP signaling pathway.

Simplified Signaling Pathway

Survodutide

↓

GLP-1R

↓

Gs Protein Activation

↓

Adenylyl Cyclase

↓

Increased Intracellular cAMP

↓

PKA and EPAC-Associated Signaling

↓

Tissue-Specific Cellular Responses

Research Areas

Receptor binding

Receptor potency

cAMP accumulation

Insulin secretion

Appetite-related signaling

Receptor internalization

Signal duration

Receptor desensitization

Biased agonism

These endpoints are useful when comparing Survodutide with other incretin-related peptides.

Survodutide and Glucagon Receptor Research

The glucagon receptor is expressed prominently in the liver.

GCGR activation influences hepatic glucose production and other metabolic pathways.

Survodutide's GCGR activity is a defining component of its dual-agonist design.

Research Areas

Hepatic cAMP signaling

Glucose metabolism

Lipid metabolism

Energy expenditure mechanisms

Hepatic substrate utilization

Receptor selectivity

Receptor activation kinetics

Metabolic adaptation

A central scientific question is whether glucagon receptor-associated effects can complement GLP-1-mediated metabolic changes without producing unacceptable glycemic or cardiovascular risks.

Why Combine GLP-1 and Glucagon Receptor Activation?

Selective GLP-1 receptor agonists can reduce food intake and improve glycemic regulation.

Glucagon receptor activation may influence hepatic lipid metabolism and energy expenditure.

Dual agonism aims to combine complementary metabolic effects.

Proposed Pharmacological Rationale

GLP-1R Component

Primarily associated with appetite regulation and glucose-dependent endocrine responses.

GCGR Component

Associated with hepatic metabolic signaling and potential energy expenditure effects.

Combined Activity

Investigated for effects on body weight, glucose homeostasis, liver fat and other metabolic outcomes.

However, the theoretical benefits of dual agonism require confirmation in clinical trials.

Dual receptor activity does not automatically mean greater efficacy or safety than a selective GLP-1 receptor agonist.

Survodutide and cAMP Signaling

Both GLP-1R and GCGR can activate Gs-associated signaling.

This leads to increased intracellular cAMP.

cAMP influences downstream proteins including protein kinase A and exchange proteins directly activated by cAMP.

Research Endpoints

cAMP production

PKA signaling

EPAC-associated responses

Receptor activation potency

Signal duration

Receptor desensitization

Cellular transcriptional responses

The physiological effects depend on which receptor is activated and the tissue being studied.

Survodutide and Appetite Regulation

GLP-1 receptor signaling is involved in regulation of appetite and food intake.

Survodutide's GLP-1R activity contributes to its relevance in obesity research.

Research Areas

Food intake

Satiety-associated signaling

Central appetite pathways

Meal-related metabolic responses

Body weight regulation

Gastrointestinal signaling

Energy balance

Clinical trials have demonstrated reductions in body weight in selected populations.

However, the relative contribution of reduced food intake versus changes in energy expenditure remains an important research question.

Survodutide and Energy Expenditure

Glucagon receptor activation has been investigated for potential effects on energy expenditure.

This is one of the scientific rationales for combining GCGR and GLP-1R activity.

Experimental Research Areas

Energy expenditure

Substrate oxidation

Hepatic metabolism

Thermogenic signaling

Metabolic adaptation

Whole-body energy balance

However, increased energy expenditure should not be presented as a universally demonstrated human effect of Survodutide.

The extent to which GCGR activation independently contributes to observed weight reduction requires further investigation.

Survodutide and Obesity Research

Obesity is a complex chronic condition involving multiple physiological and environmental factors.

Relevant biological systems include appetite regulation, energy expenditure, endocrine signaling and nutrient metabolism.

Survodutide has been investigated in adults with obesity or overweight, with and without type 2 diabetes.

Principal Clinical Endpoints

Percentage change in body weight

Proportion achieving clinically meaningful weight reduction

Waist circumference

Metabolic biomarkers

Glycemic control

Treatment discontinuation

Adverse events

Long-term weight maintenance

Clinical research has progressed from phase 2 studies to a large phase 3 program.

Survodutide Phase 2 Obesity Research

A phase 2 randomized trial evaluated Survodutide in adults with overweight or obesity without diabetes.

The study investigated body weight changes over 46 weeks.

Reported Findings

At the highest evaluated dose group in the published analysis, average body weight reduction reached approximately 18.7%, compared with approximately 2.3% in the placebo group.

These results demonstrated substantial weight reduction in the studied population.

Important Limitations

The study was conducted in a selected clinical trial population.

The reported results depended on the statistical analysis and treatment assumptions.

The study did not establish long-term safety or weight maintenance after treatment discontinuation.

The findings should not be interpreted as expected results for every individual.

Survodutide Phase 3 Research: SYNCHRONIZE-1

SYNCHRONIZE-1 evaluated Survodutide in adults with overweight or obesity without type 2 diabetes.

The trial included a 76-week treatment period.

Reported 2026 Findings

The phase 3 program reported average weight reduction of up to approximately 16.6% from baseline in a specified analysis.

The study also investigated body composition and cardiometabolic parameters.

Body Composition Substudy

A prespecified analysis reported:

Up to approximately 34% reduction in visceral fat

Up to approximately 63.1% reduction in liver fat

Lean mass loss representing no more than 11.3% of total tissue mass change at the highest evaluated dose

These values describe particular trial analyses and should not be generalized to every patient.

Research Interpretation

The results support further evaluation of Survodutide as a metabolic treatment candidate.

However, body composition findings do not establish superior muscle preservation relative to every other anti-obesity medicine.

Survodutide Phase 3 Research: SYNCHRONIZE-2

SYNCHRONIZE-2 investigated Survodutide in adults with overweight or obesity and type 2 diabetes.

The study evaluated body weight and glycemic outcomes over 76 weeks.

Results were reported in October 2026.

Published Treatment-Regimen Analysis

The mean body weight changes were:

These results reflect the treatment-regimen estimand, which accounts for treatment interruptions or discontinuation under the trial's statistical framework.

Glycemic Findings

Mean HbA1c changes were:

Survodutide 3.6 mg: −0.9 percentage points

Survodutide 6.0 mg: −0.8 percentage points

Placebo: −0.2 percentage points

The baseline mean HbA1c was approximately 7.4%.

Efficacy Estimand

A separate efficacy estimand reported weight reduction of up to 13.1%, compared with 3.1% for placebo.

The different estimands answer different statistical questions.

Their results should not be combined or presented as interchangeable.

Research Interpretation

The trial demonstrated statistically significant weight reduction compared with placebo in the studied population.

However, the results do not establish that Survodutide is superior to semaglutide or tirzepatide.

Survodutide and Type 2 Diabetes Research

Type 2 diabetes involves abnormalities in insulin secretion, insulin sensitivity and glucose regulation.

GLP-1 receptor activation can improve glucose-dependent insulin secretion.

Glucagon receptor activation can increase hepatic glucose output.

Survodutide therefore provides a useful research model for understanding how dual receptor activation influences glycemic balance.

Research Areas

HbA1c

Fasting glucose

Insulin secretion

Insulin sensitivity

Hepatic glucose production

Body weight

Metabolic biomarkers

Treatment tolerability

The SYNCHRONIZE-2 results provide human clinical evidence of improvements in selected glycemic outcomes.

However, Survodutide is not an approved diabetes medicine as of October 2026.

Survodutide and Liver Metabolism

The liver plays a central role in glucose, lipid and energy metabolism.

Excessive hepatic fat accumulation is associated with metabolic dysfunction.

Survodutide has been investigated for effects on liver fat, inflammation and fibrosis-related measurements.

Its glucagon receptor activity is particularly relevant to the scientific rationale for hepatic metabolic research.

Research Areas

Hepatic lipid accumulation

Liver fat fraction

Hepatic glucose metabolism

Liver inflammation biomarkers

Liver stiffness

Fibrosis-associated markers

Metabolic dysfunction

MASH histology

These outcomes must be interpreted separately because reduced liver fat does not necessarily demonstrate reversal of fibrosis.

What Is MASLD?

MASLD stands for metabolic dysfunction-associated steatotic liver disease.

It describes hepatic steatosis occurring in association with cardiometabolic risk factors under contemporary diagnostic criteria.

MASLD is associated with conditions including obesity, insulin resistance and type 2 diabetes.

Relevant Research Endpoints

Liver fat content

Insulin resistance

Liver enzymes

Liver stiffness

Inflammation markers

Fibrosis risk

Cardiometabolic factors

Survodutide has been investigated in clinical studies involving MASLD.

What Is MASH?

MASH stands for metabolic dysfunction-associated steatohepatitis.

It is a more inflammatory form of steatotic liver disease.

MASH can involve hepatocellular injury and varying degrees of liver fibrosis.

Important Research Measurements

Histological MASH improvement

MASH resolution

Fibrosis stage

Liver fat content

ALT and AST

Noninvasive fibrosis markers

Liver stiffness

Long-term liver outcomes

Survodutide has been investigated in biopsy-confirmed MASH and in broader at-risk MASLD populations.

These populations are not identical.

Survodutide Phase 2 MASH Research

A randomized phase 2 study evaluated Survodutide in adults with biopsy-confirmed MASH and fibrosis stages F1 through F3.

The trial lasted 48 weeks and included 293 treated participants.

Primary Endpoint

Improvement in MASH without worsening of fibrosis.

Reported Results

The study found a statistically significant dose-response relationship for the primary endpoint.

Fibrosis-Related Results

At least one-stage fibrosis improvement was observed in approximately:

34–36% of Survodutide-treated participants

22% of placebo-treated participants

These findings require careful interpretation because histological endpoints, study duration and statistical analysis affect conclusions.

The results supported progression to additional clinical research.

Survodutide Phase 3 Research: SYNCHRONIZE-MASLD

SYNCHRONIZE-MASLD was a randomized, double-blind, placebo-controlled phase 3 trial.

The study included 216 adults with obesity and at-risk MASLD.

The treatment period was 48 weeks.

Co-Primary Endpoints

At least 30% reduction in MRI-measured liver fat

Percentage change in body weight

Both co-primary endpoints were met.

Liver Fat Results

Using the efficacy estimand:

84.2% of participants receiving Survodutide achieved at least a 30% reduction in liver fat.

24.3% of participants receiving placebo achieved the same threshold.

Body Weight Results

Using the efficacy estimand:

Survodutide: −12.2%

Placebo: −1.0%

Liver Fat Normalization

Liver fat content below 5% was observed in:

61.0% of Survodutide-treated participants

5.7% of placebo-treated participants

Additional Research Findings

The study also reported improvements in selected liver-related and cardiometabolic biomarkers.

However, the trial had a relatively short duration and limited geographic recruitment.

Important Scientific Distinction

The phase 3 study primarily evaluated imaging and noninvasive liver-related outcomes.

A reduction in MRI-measured liver fat is not the same endpoint as biopsy-confirmed fibrosis regression.

The results should not be presented as proof that Survodutide reverses advanced liver fibrosis or prevents liver-related mortality.

Survodutide and Liver Fibrosis Research

Fibrosis involves accumulation of extracellular matrix associated with chronic tissue injury.

In MASH, fibrosis stage is an important predictor of long-term liver-related outcomes.

Survodutide research has examined fibrosis through histology and noninvasive measurements.

Research Areas

Fibrosis stage

Liver stiffness

Enhanced liver fibrosis scores

Inflammation markers

Liver fat

Histological disease activity

Important Limitations

Different fibrosis measurements are not interchangeable.

Liver stiffness may change due to inflammation and other physiological factors.

A reduction in liver stiffness does not necessarily prove histological fibrosis regression.

Long-term studies are needed to determine effects on clinically important liver outcomes.

Survodutide and Visceral Fat Research

Visceral adipose tissue is fat located around internal abdominal organs.

Excess visceral fat is associated with cardiometabolic risk.

Survodutide has been investigated for effects on visceral fat and body composition.

Research Areas

Visceral adipose tissue volume

Total fat mass

Lean mass

Body weight

Waist circumference

Metabolic risk markers

The SYNCHRONIZE-1 body composition analysis reported substantial reductions in visceral fat.

However, the reported percentages reflect specific analyses and should not be interpreted as guaranteed individual outcomes.

Survodutide and Cardiometabolic Research

Cardiometabolic health involves interactions among body weight, glucose metabolism, blood pressure and lipid regulation.

Survodutide clinical studies have evaluated multiple cardiometabolic measurements.

Research Endpoints

Body weight

Waist circumference

HbA1c

Insulin resistance

Triglycerides

Cholesterol

Blood pressure

Liver-related biomarkers

Inflammation markers

Improvements in risk markers do not automatically establish reductions in cardiovascular events.

Cardiovascular outcome evidence must be evaluated separately.

Survodutide and Cardiovascular Outcomes

Cardiovascular safety and efficacy are important components of long-term metabolic drug development.

Large clinical programs may evaluate outcomes such as:

Cardiovascular death

Nonfatal myocardial infarction

Nonfatal stroke

Heart failure-related events

Treatment-associated cardiovascular adverse events

As of October 2026, definitive evidence that Survodutide reduces major adverse cardiovascular events has not been established.

A favorable change in weight, HbA1c or blood pressure should not be described as proven cardiovascular event prevention.

Survodutide and Insulin Resistance

Insulin resistance occurs when cells respond less effectively to insulin.

It is associated with obesity, type 2 diabetes and MASLD.

Survodutide studies have investigated insulin resistance-related biomarkers.

Research Areas

HOMA-IR

Glucose metabolism

Hepatic insulin sensitivity

Body weight-associated metabolic changes

Adipose tissue biology

Metabolic inflammation

Some clinical findings suggest favorable changes in selected insulin resistance measurements.

However, mechanistic attribution requires careful investigation.

Survodutide and Lipid Metabolism

Lipid metabolism involves synthesis, transport, storage and utilization of fatty acids and other lipids.

Both GLP-1R and GCGR signaling can influence metabolic pathways relevant to lipid regulation.

Research Areas

Hepatic triglyceride accumulation

Lipid oxidation

Adipose tissue metabolism

Circulating triglycerides

Lipoprotein-associated biomarkers

Liver fat content

Metabolic flexibility

Survodutide's dual-receptor pharmacology provides a basis for investigating these processes.

Survodutide and Energy Balance

Energy balance is influenced by energy intake and energy expenditure.

GLP-1R activity can influence appetite and food intake.

GCGR activity may influence hepatic metabolism and energy expenditure.

Experimental Questions

What proportion of weight reduction is attributable to food intake?

Does GCGR activation alter energy expenditure in humans?

How does metabolic adaptation change during treatment?

How do responses differ across metabolic phenotypes?

What happens after treatment discontinuation?

These questions remain relevant to Survodutide research.

Survodutide and Body Composition

Body weight reduction may involve changes in fat mass, lean mass and body water.

Body composition analysis is therefore important in obesity research.

Relevant Measurements

Total fat mass

Visceral fat

Subcutaneous fat

Lean body mass

Skeletal muscle-related measurements

Body water

Physical function

Preservation of lean mass cannot be inferred solely from percentage weight loss.

Different studies may use different body composition methods and analytical definitions.

Survodutide vs. Semaglutide

Semaglutide is a selective GLP-1 receptor agonist.

Survodutide activates both GLP-1R and GCGR.

Survodutide's dual receptor activity does not establish superiority over semaglutide.

Head-to-head clinical trials are needed for reliable comparative conclusions.

Survodutide vs. Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist.

Survodutide is a dual glucagon/GLP-1 receptor agonist.

Receptor Comparison

Survodutide

GLP-1R + GCGR

Tirzepatide

GIPR + GLP-1R

These peptides have different receptor profiles.

Results from separate clinical trials cannot establish which compound is more effective.

Survodutide vs. Retatrutide

Retatrutide is an investigational triple receptor agonist.

It targets GLP-1R, GIPR and GCGR.

Survodutide targets GLP-1R and GCGR.

The addition of a third receptor target does not automatically establish superior clinical outcomes.

Receptor potency, selectivity, exposure and tolerability all influence pharmacological effects.

Survodutide vs. Mazdutide

Mazdutide is another GLP-1/glucagon receptor dual agonist.

Both compounds are relevant to dual-receptor metabolic peptide research.

Shared Research Themes

GLP-1R activation

GCGR activation

Body weight regulation

Glucose metabolism

Hepatic metabolic signaling

Key Distinction

Survodutide and mazdutide are different molecular entities.

They differ in peptide design, receptor pharmacology, pharmacokinetics and clinical development history.

They should not be treated as interchangeable compounds.

Regulatory status also varies by jurisdiction and product.

Survodutide vs. Cagrilintide

Cagrilintide is a long-acting amylin analogue.

Its pharmacological mechanism differs from Survodutide.

Survodutide

GLP-1R and GCGR activation

Cagrilintide

Amylin receptor-associated signaling

Both compounds have been investigated in weight-management research, but they target different biological pathways.

Survodutide vs. Natural Glucagon

Natural glucagon is a peptide hormone that activates GCGR.

Survodutide is a modified peptide with activity at both GCGR and GLP-1R.

Differences

Natural Glucagon: Primarily glucagon receptor signaling.

Survodutide: Dual GLP-1 and glucagon receptor agonism.

Survodutide is not simply a longer-acting version of unmodified glucagon.

Its receptor pharmacology and molecular architecture are distinct.

Survodutide Safety and Tolerability

Clinical studies have reported adverse events associated with Survodutide.

Gastrointestinal adverse events are particularly relevant.

Commonly Reported Adverse Events

Nausea

Vomiting

Diarrhea

Other gastrointestinal symptoms

In SYNCHRONIZE-2, gastrointestinal adverse events were reported in approximately:

72.8% of participants in the 3.6 mg study arm

77.7% of participants in the 6.0 mg study arm

38.6% of participants in the placebo arm

These results reflect the studied clinical trial population.

Additional Safety Considerations

Dehydration associated with gastrointestinal symptoms

Potential gallbladder-related events

Pancreatic safety monitoring

Glucose-related effects

Heart rate and cardiovascular parameters

Treatment discontinuation

Hypersensitivity

Long-term tolerability

Not every risk listed above has been established as a causal adverse effect of Survodutide; some are important areas of monitoring based on its pharmacological class and clinical development.

Important Limitation

The safety of pharmaceutical clinical trial formulations cannot be assumed to apply to research-grade products.

Survodutide and Pancreatic Research

GLP-1 receptor activation influences pancreatic endocrine physiology.

Survodutide's GLP-1R activity is relevant to research involving pancreatic beta-cell signaling.

Research Areas

Glucose-dependent insulin secretion

Beta-cell signaling

cAMP-associated pathways

Glucagon regulation

Endocrine feedback

Pancreatic safety

Claims that Survodutide regenerates pancreatic beta cells or cures diabetes are not established.

Survodutide and Long-Term Weight Maintenance

Long-term weight maintenance is a major question in obesity pharmacotherapy.

Relevant issues include:

Duration of treatment response

Treatment discontinuation

Weight regain

Metabolic adaptation

Adherence

Safety over multiple years

Effects on cardiovascular outcomes

Although phase 3 studies provide important efficacy information, long-term outcomes after discontinuation remain incompletely characterized.

Survodutide and Peptide Pharmacokinetics

Survodutide incorporates structural modifications intended to extend its pharmacological exposure.

Lipidation is a recognized strategy in long-acting peptide design.

Pharmacokinetic Research Areas

Absorption

Distribution

Protein binding

Metabolic stability

Clearance

Half-life

Receptor exposure

Pharmacodynamic duration

The pharmacokinetic behavior of a peptide depends on the precise molecular structure and formulation.

Data from pharmaceutical trials should not be generalized to products with different analytical or formulation characteristics.

Survodutide Peptide Stability

Modified peptides can undergo chemical and physical degradation.

Potential stability concerns include:

Hydrolysis

Oxidation

Deamidation

Aggregation

Adsorption

Temperature-associated degradation

pH-dependent instability

Impurity formation

Lipidated side-chain degradation

Validated stability data are necessary to establish appropriate storage conditions for a specific research preparation.

Survodutide Analytical Characterization

Reliable research requires accurate molecular identity and purity verification.

Survodutide's modified structure creates additional analytical considerations compared with simple unmodified peptides.

Important Quality Parameters

Verified molecular identity

Molecular formula

Molecular mass

Peptide backbone

Nonstandard amino acid identity

Lipidated modification

C-terminal amidation

Peptide purity

Peptide content

Counterion composition

Residual reagents

Related substances

Batch-specific documentation

High-Performance Liquid Chromatography

HPLC is commonly used to evaluate peptide purity.

An appropriate method should distinguish the principal compound from relevant impurities.

Research Considerations

Chromatographic purity

Related peptide impurities

Degradation products

Method specificity

Batch consistency

A high HPLC purity percentage does not independently establish correct molecular identity or suitability for clinical administration.

Liquid Chromatography–Mass Spectrometry

LC-MS can help verify the molecular mass of Survodutide.

The expected molecular weight of the defined Survodutide entity is approximately 4,231.7 g/mol.

Mass spectrometry can also assist in identifying certain molecular modifications and degradation products.

However, molecular mass alone may not fully verify the precise location of every structural modification.

Peptide Content Analysis

Peptide content testing is distinct from chromatographic purity.

A research preparation may contain:

The principal peptide

Counterions

Residual water

Other non-peptide material

Accurate peptide content information is important for quantitative laboratory research.

Certificate of Analysis

A batch-specific Certificate of Analysis should provide relevant analytical information.

Recommended documentation includes:

• Product name

• Batch or lot number

• Molecular identity

• Molecular formula

• Molecular weight

• Peptide sequence or structural description

• Lipidated modification

• Peptide purity

• Peptide content

• Counterion information

• Analytical methods

• Impurity profile

• Stability-related information

A Certificate of Analysis does not establish clinical safety, sterility or pharmaceutical authorization.

Survodutide Clinical Evidence: Established Findings and Limitations

Findings Supported by Clinical Research

• Survodutide is a GLP-1/glucagon receptor dual agonist.

• It has demonstrated weight reduction compared with placebo in selected clinical trial populations.

• Phase 3 studies have reported positive body weight endpoints.

• SYNCHRONIZE-2 demonstrated statistically significant weight reduction in adults with obesity or overweight and type 2 diabetes.

• SYNCHRONIZE-MASLD demonstrated significant reductions in MRI-measured liver fat and body weight.

• Phase 2 MASH research reported improvement in selected histological endpoints.

• Gastrointestinal adverse events are common in clinical trials.

Important Limitations

• Survodutide remains investigational as of October 2026.

• It is not an FDA-approved obesity or diabetes treatment.

• Long-term cardiovascular outcome benefits have not been established.

• Direct superiority over semaglutide or tirzepatide has not been established.

• Results from different trials cannot be directly compared without appropriate methodology.

• Weight maintenance after treatment discontinuation remains uncertain.

• Liver fat reduction is not equivalent to proven fibrosis reversal.

• Long-term safety requires further characterization.

• Research-grade Survodutide is not equivalent to clinical trial medication.

• No evidence supports unsupervised human use of research-grade Survodutide.

Potential Survodutide Research Applications

Survodutide may be relevant to appropriately controlled scientific investigations involving:

• GLP-1 receptor pharmacology

• Glucagon receptor pharmacology

• Dual receptor agonism

• Class B GPCR signaling

• Gs protein activation

• cAMP signaling

• PKA-associated pathways

• EPAC-associated signaling

• Receptor selectivity

• Receptor potency

• Metabolic hormone research

• Appetite-related signaling

• Energy balance

• Hepatic glucose metabolism

• Lipid metabolism

• Insulin secretion

• Glucose homeostasis

• Obesity biology

• Body composition

• Visceral adipose tissue

• MASLD research

• MASH research

• Hepatic steatosis

• Liver inflammation biomarkers

• Fibrosis-associated markers

• Cardiometabolic physiology

• Peptide pharmacokinetics

• Lipidated peptide chemistry

• Peptide analytical characterization

These research areas do not establish therapeutic benefits of ICAME Pharmacy research products.

Survodutide Research Overview

Compound Name: Survodutide

Development Code: BI 456906

Classification: Synthetic Dual-Receptor Agonist Peptide

Receptor Targets: GLP-1R and GCGR

Molecular Formula: C₁₉₂H₂₈₉N₄₇O₆₁

Molecular Weight: Approximately 4,231.7 g/mol

CAS Number: 2805997-46-8

PubChem CID: 168429725

Molecular Structure: Modified Lipidated Peptide

Principal Signaling: GLP-1R/GCGR-Associated GPCR Signaling

Research Areas: Metabolic Regulation / Obesity / MASLD / MASH / Glucose Homeostasis

Clinical Development: Phase 3

FDA Status (October 2026): Investigational — Not Approved

ICAME Product Status: Research Use Only

ICAME Pharmacy Product Information

Product Name: Survodutide

Alternative Name: BI 456906

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: GLP-1/Glucagon Dual Receptor Agonist

Research Areas: Metabolic Science / Receptor Pharmacology / Liver Biology / Cardiometabolic Research

Intended Use: Laboratory Research & Development Only

Product specifications should be verified using batch-specific analytical documentation.

Important documentation includes:

• Molecular identity

• Modified peptide structure

• Molecular mass

• Peptide purity

• Peptide content

• Lipidated side-chain identity

• Counterion composition

• Impurity profile

• Analytical methodology

• Certificate of Analysis

• Batch or lot identification

• Validated stability information

No claims of pharmaceutical quality, sterility, injectable suitability or equivalence to clinical trial formulations should be made without appropriate supporting documentation.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, weight-loss, diabetes treatment, bodybuilding, athletic performance enhancement or other clinical purposes. Not for direct administration to humans or animals.

Survodutide is an investigational GLP-1/glucagon receptor dual agonist that has been evaluated in phase 2 and phase 3 clinical trials.

Although clinical studies have reported promising results in selected metabolic and liver-related endpoints, Survodutide is not an FDA-approved medicine as of October 2026.

ICAME Pharmacy Survodutide is a research product and is not equivalent to pharmaceutical formulations used in clinical trials.

Clinical study results do not establish the safety, efficacy or suitability of research-grade Survodutide for human administration.

Information on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, receptor pharmacology, metabolic signaling, endocrinology, molecular biology and analytical chemistry.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About Survodutide

What is Survodutide?

Survodutide is an investigational synthetic peptide that activates GLP-1 and glucagon receptors.

What is another name for Survodutide?

Its development code is BI 456906.

What is the molecular formula of Survodutide?

C₁₉₂H₂₈₉N₄₇O₆₁.

What is the molecular weight of Survodutide?

Approximately 4,231.7 g/mol.

What is the CAS number of Survodutide?

2805997-46-8.

What is the PubChem CID of Survodutide?

What receptors does Survodutide activate?

GLP-1R and GCGR.

Is Survodutide a GLP-1 peptide?

It is a modified peptide with GLP-1 receptor agonist activity and additional glucagon receptor agonist activity.

Is Survodutide a dual agonist?

Yes. It is a GLP-1/glucagon receptor dual agonist.

Is Survodutide the same as semaglutide?

No. Semaglutide selectively activates GLP-1R, while Survodutide activates GLP-1R and GCGR.

Is Survodutide the same as tirzepatide?

No. Tirzepatide activates GIPR and GLP-1R, while Survodutide activates GCGR and GLP-1R.

Is Survodutide the same as retatrutide?

No. Retatrutide is an investigational triple agonist targeting GLP-1R, GIPR and GCGR.

What is the difference between Survodutide and mazdutide?

Both have GLP-1/glucagon dual agonist activity, but they are distinct molecular entities with different clinical development histories.

Has Survodutide been studied in humans?

Yes. Multiple phase 2 and phase 3 clinical trials have been conducted.

Does Survodutide reduce body weight?

Clinical trials have demonstrated significant body weight reductions compared with placebo in selected populations.

What did SYNCHRONIZE-1 investigate?

It investigated Survodutide in adults with obesity or overweight without type 2 diabetes.

What did SYNCHRONIZE-2 investigate?

It investigated Survodutide in adults with obesity or overweight and type 2 diabetes.

What did SYNCHRONIZE-MASLD investigate?

It investigated Survodutide in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease.

Does Survodutide reduce liver fat?

Clinical studies have reported significant reductions in MRI-measured liver fat in selected populations.

Does Survodutide cure fatty liver disease?

No. A cure has not been established.

Does Survodutide reverse liver fibrosis?

Some research has reported improvements in fibrosis-related endpoints, but generalized reversal of liver fibrosis has not been established.

Does Survodutide improve blood glucose?

Clinical research has reported improvements in HbA1c in selected populations with type 2 diabetes.

Is Survodutide better than semaglutide?

Direct comparative superiority has not been established.

Is Survodutide better than tirzepatide?

Direct comparative superiority has not been established.

Is Survodutide FDA-approved?

No. As of October 2026, Survodutide remains investigational.

What are the most common adverse events reported in Survodutide studies?

Nausea, vomiting, diarrhea and other gastrointestinal symptoms.

Is Survodutide safe for human use?

Clinical trial formulations have undergone controlled safety evaluation, but the compound is not approved for routine clinical use. Research-grade Survodutide has not been established as suitable for human administration.

Is ICAME Pharmacy Survodutide intended for human use?

No. ICAME Pharmacy Survodutide is intended strictly for laboratory research and development purposes.